Clinical trials: CART Cells
Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer
CART-meso in Mesothelin Expressing Cancers
Phase I study to establish safety and feasibility of intravenously administered lentiviral transduced CART-meso cells administered with and without cyclophosphamide in a 3+3 dose escalation design in patients with metastatic…
- Conditions
- Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer, Malignant Epithelial Pleural Mesothelioma
- Trial name
- NCT02159716
- Testing
- CART-meso
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pennsylvania
Glioblastoma
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with…
- Trial name
- NCT05168423
- Testing
- CART-EGFR-IL13Ra2 Cells
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Pennsylvania
Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
The objective of this study was to evaluate the safety and efficacy of CD180 CART cells in the treatment of patients with relapsed/refractory CD180-positive hematological malignancies.
- Trial name
- NCT07106749
- Testing
- CD180 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Castrate-Resistant Prostate Cancer
PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer
PD1-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
- Trial name
- NCT04768608
- Testing
- PD1-PSMA-CART cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Zhejiang University
CART Treatment, B Cell Lymphoma
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART
Treatment with chimeric antigen receptor-T cell (CAR-T) is successful in patients who have not responded to chemotherapy or bone marrow transplantation but it may provoke side effects and long-term complications.
- Trial name
- NCT05286164
- Testing
- Eltrombopag
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
- Trial name
- 24CT015 (NCT06934382)
- Testing
- Allogeneic anti-CD7 CAR-T cells (BEAM-201)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Stephan Grupp MD PhD
Refractory Lupus Nephritis, Systemic Sclerosis
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension
- Trial name
- NCT06947473
- Testing
- umbilical cord blood CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
B-cell Malignancies
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
The study will evaluate safety and efficacy of a 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) for patients with B cell malignancies.
- Trial name
- NCT03050190
- Testing
- Therapeutic 4SCAR19 cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Malignant Neoplasms of Digestive Organs
CART Therapy in Digestive System Tumors
Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric…
- Trial name
- NCT04780529
- Testing
- gucy2c cart cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Innovative Cellular Therapeutics Co., Ltd.
Leukemia, Leukemia, Lymphoblastic
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell
This protocol will develop an observational cohort of PLWH who have been or are being treated with CAR19 therapy outside of an AMC clinical trial.
- Conditions
- Leukemia, Leukemia, Lymphoblastic, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma
- Trial name
- CS22-03 (NCT05784415)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- AIDS Malignancy Consortium
Glioblastoma
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
This is an open-label phase 1 study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as…
- Trial name
- NCT06973096
- Testing
- CART-EGFR-IL13Ra2 cells, Rituximab or Rituximab biosimilar, Fludarabine + Cyclophosphamide combination
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy.
- Trial name
- NCT06185751
- Testing
- WS-CART-CS1, Lymphodepleting chemotherapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Adult Acute Myeloid Leukemia
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Patients with acute myeloid leukemia(AML) recurred after the allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a dismal prognosis.The investigators developed donor-derived chimeric antigen receptor modified-T…
- Trial name
- NCT03114670
- Testing
- CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
This non-randomized, open label, multi-site, first-in-human, Phase 1/2 study CRC-403 will evaluate the safety and efficacy of bbT369 in subjects with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT05169489
- Testing
- bbT369
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
This is a single center, single arm Phase I study to establish the safety and feasibility of intravenously administered lentivirally transduced dual PSMA-specific/TGFβ-resistant CAR modified autologous T cells (CART-PSMA-TGFβRDN…
- Trial name
- NCT03089203
- Testing
- CART-PSMA-TGFβRDN cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Pennsylvania
Plasma Cell Leukemia
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma…
- Trial name
- NCT05870917
- Testing
- anti-BCMA CAR-T, VRD-based Regimen
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Carcinoma, Hepatocellular
A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
In this study, CART cells are targeted to GPC3 by intratumor injected that we hope by this means could improve the local CAR-T cell numbers, meanwhile reduce the potential side effects.
- Trial name
- NCT03130712
- Testing
- GPC3-CART cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai GeneChem Co., Ltd.
Leukemia, B-Cell
Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and clinical activity of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in treating patients with recurrent or refractory CD19 positive B cell ccute lymphoblastic…
- Trial name
- NCT03599375
- Testing
- CD19-targeted CART cells
- Volunteers
- 20 people
- Sponsor
- jiuwei cui
Multiple Myeloma
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
This is a Phase 1, multicenter, open-label study o evaluate the safety and efficacy of CART-BCMA in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT05346198
- Testing
- CART-BCMA
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
ALL, Childhood B-Cell
Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate the safety and tolerability of CD19-Directed Allogeneic Chimeric Antigen Receptor T- cell (alloCART-19)therapy in pediatric patients with relapsed/refractory acute lymphoblastic…
- Trial name
- NCT04173988
- Testing
- alloCART-19, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Children's Hospital of Fudan University